Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia

Treatment of chronic lymphocytic leukemia (CLL) has advanced with the introduction of chemoimmunotherapy (CIT) agents that have improved the outcomes of frontline therapy. However, most treated patients will relapse and require subsequent therapy. This review focuses on recent advances in the treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Shustik, C., Bence-Bruckler, I., Delage, R., Owen, C. J., Toze, C. L., Coutre, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486803/
https://www.ncbi.nlm.nih.gov/pubmed/28389687
http://dx.doi.org/10.1007/s00277-017-2982-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486803/
https://www.ncbi.nlm.nih.gov/pubmed/28389687
http://dx.doi.org/10.1007/s00277-017-2982-1

Ejemplares similares